23andMe Welcomes Expert Insights with New Board Members
23andMe Research Institute Expands Board of Directors
23andMe Research Institute has recently added Brad Margus and Stephen Quake, D.Phil., to its Board of Directors, enhancing the organization's expertise in genetics and research.
Strategic Leadership for Future Impact
The introduction of these distinguished figures aims to bolster the Institute's vision of utilizing genetic research for the betterment of health and wellness globally. Founder Anne Wojcicki expressed enthusiasm about their appointments, noting their wealth of experience in genetics and nonprofit leadership.
Brad Margus: A Passionate Advocate for Genetic Research
As the founder and chairman of the A-T Children's Project, Margus champions research focused on ataxia telangiectasia (A-T), a rare disease impacting his family. His credentials extend to founding Cerevance, a pioneering drug discovery company aiming to confront brain diseases. Notably, under his direction, the firm is progressing in advanced clinical trials for its drug addressing Parkinson's Disease.
Steve Quake: Innovating the Future of Genomics
With profound expertise, Stephen Quake has significantly influenced the field of bioengineering. As a professor at Stanford University, he leads pioneering research and is recognized for developing remarkable sequencing technologies and analyses vital for modern medical diagnostics.
Collaborative Efforts Towards Better Health
Joining Margus and Quake on the board are distinguished scientists and executives, including founder Anne Wojcicki, who foster a collaborative environment focused on groundbreaking genetic insights.
About 23andMe Research Institute
The 23andMe Research Institute stands dedicated to advancing scientific knowledge about genetics. By encouraging participation in a broad research initiative, the Institute strives to deepen the global understanding of DNA and its implications for individual health.
Contact Information
If you wish to learn more or get involved, please reach out to the 23andMe Research Institute through their press contact at press@23andme.com.
Frequently Asked Questions
What is the purpose of the 23andMe Research Institute?
The Institute aims to provide people access to their genetic information and be a leader in crowdsourced genetic research.
Who are the new members of the Board of Directors?
Brad Margus and Stephen Quake, D.Phil., have joined to enhance the organization’s strategic direction and operational impact.
What are the backgrounds of Brad Margus and Stephen Quake?
Margus is known for his work in non-profit and biotech, while Quake is a prominent bioengineering professor recognized for his innovations in genomics.
How does 23andMe contribute to health and research?
By facilitating detailed genetic research, 23andMe fosters advancements that improve health outcomes based on genomic insights.
How can I get involved with 23andMe Research Institute?
Interested individuals can reach out via press@23andme.com to explore participation or inquiries related to the Institute.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.